Trial Profile
A study on the effect of improving the QOL (quality of life), response and safety of eribulin mesylate for inoperable or recurrent breast cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 May 2013
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 27 May 2013 New trial record